Objective To compare the clinical safety and effectiveness of domestic clopidogrel (Talcom) and imported clopidogrel (Plavix) in the patients after percutaneous coronary intervention (PCI). Methods A total of 210 patients with coronary heart disease (CHD) were randomly divided into two groups, including Talcom group (n=103) and Plavix group (n=107). All patients were given 300 mg of aspirin (once per day), 300 mg of clopidogrel for the loading dosage and then 75 mg of clopidogrel (once per day) for one year. For patients with triple vessel disease, 300 mg of clopidogrel for the loading dosage, 150 mg of clopidogrel (once per day) for two weeks, and then 75 mg of clopidogrel (once per day) for one year were administrated. The primary endpoints included major adverse cardiac and cerebral events (including cardiac death, stent thrombosis, in-stent restenosis, non-fatal myocardial infarction, target vessel revascularization) and stroke for 6 months. The secondary endpoints were hemorrhage events and change of platelet aggregation rate. Results There was no significant difference in the incidence of major cardiovascular diseases between Talcom group and Plavix group (P＞0.05). As for the rate of platelet aggregation and general incidence of bleeding events at 6 months, no significantly difference was found between the two groups. Conclusion The domestic clopidogrel (Talcom), as an anti-platelet drug, is safe and effective for patients undergoing drug eluting stent in 6 months.